[Examination of effectiveness of olopatadine hydrochloride in atopic dermatitis].
Subjective/objective symptoms (itching, papula, erythema, lichenification, desquamation, scratching, erosion) and the levels of IgE, LDH, interleukin (IL) -6, thymus and activation-regulated chemokine (TARC) were compared before and after administering olopatadine hydrochloride (ALLELOCK tablets) to 17 atopic dermatitis (AD) patients. Subject/objective symptoms improved significantly after administering the agent, and the total dosage of the combined topical steroids was also significantly decreased after administration (p<0.05), although IgE, IL-6 and LDH levels did not change, TARC was significantly decreased (p<0.05). The correlation between the levels of IgE, IL-6, LDH and TARC before and after the administration was examined. There was a positive correlation between IgE and TARC (r=0.62, p<0.01) and between IL-6 and TARC (r=0.78, p<0.01). Olopatadine hydrochloride is therefore useful in improving the symptoms in AD, and TARC may be used as an indicator of the symptom improvement.
Shimizu
Tadamichi
T
Department of Dermatology, Hokkaido University Graduate School of Medicine. michiki@med.hokudai.ac.jp
Mashiko
Maki
M
Shimizu
Hiroshi
H
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D054414:Chemokine CCL17; D019742:Chemokines, CC / Q000097:blood*; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000503:physiopathology; D003990:Dibenzoxepins / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D000069605:Olopatadine Hydrochloride
D000894:Anti-Inflammatory Agents, Non-Steroidal; C106230:CCL17 protein, human; D054414:Chemokine CCL17; D019742:Chemokines, CC; D003990:Dibenzoxepins; D015850:Interleukin-6; D000069605:Olopatadine Hydrochloride; D007073:Immunoglobulin E